Gatera Vesara Ardhe, Abdulah Rizky, Musfiroh Ida, Judistiani Raden Tina Dewi, Setiabudiawan Budi
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.
Adv Pharmacol Sci. 2018 Sep 30;2018:8494816. doi: 10.1155/2018/8494816. eCollection 2018.
To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. The common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. The metabolized form of vitamin D used in these studies was 1,25(OH)D in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.
为更新有关呼吸窘迫综合征中维生素D状态的指南,我们回顾了近期关于维生素D对呼吸窘迫有益作用的人类和动物研究。我们在PubMed和ProQuest上搜索了2009年至2017年期间关于维生素D使用的研究。这些研究中的常见参数包括使用肺组织、磷脂、血液和血浆来评估维生素D对呼吸综合征的影响。这些研究中使用的维生素D代谢形式在动物研究中为1,25(OH)D,在人类研究中为25(OH)D。补充维生素D可降低呼吸窘迫综合征的风险,改善生活质量,对早产儿以及肺成熟过程相对有效且安全。然而,尽管补充维生素D可能对呼吸窘迫综合征有益,但必须明确针对肺部特定类型风险因素的最佳给药策略,以确认其治疗效果。